PDCD1 and melanoma: Bicarbonate administration has been reported to control melanoma growth, increase CD8+ T cell infiltration and NK and B cell activation, and improve anti-CTLA4 and anti–PD-1 therapy and adoptive cell therapy in B16 melanoma–bearing mice [109,110].